We are creating iPSC-derived T-cell organoids for studying immune responses, cancer therapy potential, and personalised treatments, opening new frontiers in regenerative and precision medicine.
Impact
This research aims to create functional blood stem cells from iPSCs, advancing therapies for blood diseases and improving our understanding of human haematopoiesis and regenerative medicine
reNEW research
5 years into developing expertise in hPSC-derived haematopoiesis, I focus on evaluating human blood cell function in vitro and in animal models to advance stem cell-based blood therapies.
Image description
Artificial thymic organoid from iPSCs with GFP-tagged HSCs differentiated into T cells in vitro.
Credits
Dr Gulcan Sarila, Research Officer, Dr Kat Goodall, Senior Research Officer, Elefanty Lab, reNEW Melbourne.
